BioSpace News Archive

Apex Physics Partners (APP), a leading medical physics business services support organization, is proud to announce a new partnership with Alyzen Medical Physics, a leader in therapy medical physics services.

In response to Hurricane Isaias, which has led the governors of South Carolina , North Carolina and Virginia to declare states of emergency, Blue Cross Blue Shield of Massachusetts (Blue Cross), Inc. is expediting access to care for affected members.

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in oncology and viral diseases announced today that the National Institute for Dental and Craniofacial Rese

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.

IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021.

GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company, announced the launch of GenomeXpress, a rapid genome sequencing test.

-- Collaboration will focus on direct-to-consumer and traditional retail channels, in key emerging markets including China and Israel --

Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations, leveraging his deep expertise in digitalization to drive productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806005031/en/ Crown Bioscience Chief Operations Officer Joh

Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney disease on dialysis Maintains strong balance sheet with $204.8 million in cash, cash equivalents and short-term investments

Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s remarks. The con